ERBB2 and breast cancer: Richard S. Finn from the University of California, Los Angeles has now supplemented these with “dramatic, significant and clinically meaningful” results of a Phase II study of this candidate drug in postmenopausal women with ER-positive/HER2-negative breast cancer, most with metastatic disease.